This trial is testing a new treatment for men with prostate cancer that has progressed even after other treatments. The new treatment is a combination of high dose testosterone and Enzalutamide, and the goal is to see if it is better than the standard treatment (just Enzalutamide) at improving the primary and secondary objectives.
1 Primary · 7 Secondary · Reporting Duration: Up to 3 years
150 Total Participants · 3 Treatment Groups
Primary Treatment: Testosterone enanthate · No Placebo Group · Phase 2
Age 18+ · Male Participants · 10 Total Inclusion CriteriaMark “Yes” if the following statements are true for you: